Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039180 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02039180 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 1 participants.
The verdict
NCT02039180, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open-label, randomized, 3-period crossover, single dose study. Three (3) single doses of AZD3293 (2 different tablet formulations, and an oral solution) will be administered with a washout period of at least 1 week between the doses to investigate the relative bioavailability of AZD3293 after administration via 2 tablet formulations compared with oral solution and to evaluate basic systemic pharmacokinetic parameters of the tablet formulations compared to the oral solution of AZD3293. The safety and tolerability of AZD3293 in healthy subjects will also be assessed in the study. AZD3293 is being developed for the treatment of Alzheimer's disease
Interventions
- DRUG AZD3293 oral solution
- DRUG AZD3293 tablet formulation A
- DRUG AZD3293 tablet formulation B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02039180
The ClinicalTrials.gov registry entry for NCT02039180 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AZD3293 oral solution is the first listed.
NCT02039180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02039180 about?
NCT02039180 is a clinical study titled "Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects". This is an open-label, randomized, 3-period crossover, single dose study. Three (3) single doses of AZD3293 (2 different tablet formulations, and an oral solution) will be administered with a washout period of at least 1 week between the doses to investigate the relative bioavailability of AZD3293 a...
What is the current status of trial NCT02039180?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2014-02. Estimated completion is 2014-03.
What interventions are being tested in trial NCT02039180?
The interventions under investigation include: AZD3293 oral solution (DRUG), AZD3293 tablet formulation A (DRUG), AZD3293 tablet formulation B (DRUG).
Who is sponsoring clinical trial NCT02039180?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.